Ajinomoto Co., Ltd.

Atsushi Konishi

Tamotsu Suzuki

Koji Ohsumi

Munetaka Tokumasu

Takahiro Koshiba

Osamu Ikehara

Yuko Kodama

Tsuyoshi Kobayashi

Takashi Yamamoto

Toshihiro Hatanaka

Yukio Iino

Koichi Fujita

Kenji Takehana

Ariko Kodaira

Compounds represented by formula (I): wherein each symbol is as defined in the description, and pharmaceutically acceptable salts thereof are useful as hyperglycemic inhibitors having a serine protease inhibitory action and as prophylactic or therapeutic drugs for diabetes.

Heteroarylcarboxylic acid ester derivative

Compounds represented by formula (I): wherein each symbol is as defined in the description, and pharmaceutically acceptable salts thereof are useful as hyperglycemic inhibitors having a serine protease inhibitory action and as prophylactic or therapeutic drugs for diabetes. 

The present invention provides an AP-1 activation inhibitor, a NF-kappaB activation inhibitor, an inflammatory cytokine production inhibitor, a production inhibitor for matrix metalloprotease or an inflammatory cell adhesion factor expression inhibitor, which contains a heterocyclic compound or a pharmaceutically acceptable salt thereof as an active ingredient.

Heterocyclic compounds and medical use thereof

Growing community of inventors

Kawasaki, Japan

Atsushi Konishi